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Purpose: To determine whether internal limiting membrane (ILM) peeling is cost-effective compared with no peeling for patients with idiopathic stage 2 or 3 full-thickness macular hole (FTMH).

Methods: A cost-effectiveness analysis was performed alongside a randomised controlled trial (RCT).  141 participants were randomly allocated to receive macular hole surgery, with either ILM peeling or no peeling.  Health service resource use, costs and quality of life were calculated for each participant.  Incremental cost per quality-adjusted life year (QALY) gained was calculated at 6 months.

Results: At 6 months total costs were on average higher (£424, 95% CI -182 to 1045) in the No Peel arm; primarily due to the higher reoperation rate in the No Peel arm.  The mean additional QALYs from ILM peel at six months were 0.002 (95% CI 0.01 to 0.013), adjusting for baseline EQ-5D and other minimisation factors.  A mean incremental cost per QALY was not computed as Peeling was on average less costly and slightly more effective.  A stochastic analysis suggested that there was more than a 90% probability that Peeling would be cost-effective at a willingness to pay threshold of £20,000 per QALY.  








A full-thickness macular hole (FTMH) is a common retinal condition associated with impaired vision. Randomised controlled trials (RCTs) have demonstrated that surgery is effective for the treatment of FTMH [1,2]. Internal limiting membrane (ILM) peeling was introduced as an additional manoeuvre in to increase the success of the surgery.  The results from two small RCTs support the superiority of ILM peeling compared with no-peeling techniques in achieving macular hole closure [3,4]   To date the cost-effectiveness of ILM peeling compared with no-peeling techniques is not available.  In this paper, we report the economic evaluation conducted as part of the Full-thickness macular hole and Internal Limiting Membrane peeling Study (FILMS).  

METHODS
The FILMS randomised controlled trial was undertaken in the UK and Ireland and its design (\o "Lois, 2008 #3") and clinical effectiveness data (\o "Lois,  #4") are reported elsewhere [5,6].  Within the economic evaluation the costs that fall on the health service were collected along with health related outcomes.  The latter were valued in terms of quality adjusted life years (QALYs), derived from responses to the EQ-5D questionnaire.  The perspective taken was that of the UK National Health Service (NHS).  

Estimation of resource use
Resource use and costs were estimated for every trial participant from data collected within the trial, supplemented by routine data sources.  Resource use information was categorised as: 1) resources and costs required to provide the intervention; 2) resources and costs related to the use of other secondary care services; 3) resources and costs related to the use of primary care services.

1.	Resources and costs required to provide the intervention
The resources required to provide the intervention were divided into six categories: (1) anaesthetic resource use (2) surgical equipment and pathology services (3) inpatient stay for the index admission (4) use of theatre and recovery room facilities (5) Staff  (6) NHS travel.  Anaesthetic and surgical costs included all drugs and equipment used during surgery.  Local and general anaesthetic costs were fixed, with the cost of medications derived from routine sources (British National Formulary 57).  The use of surgical equipment was based on a standard ILM peel and no peel operation conducted by NHS Grampian, the cost of the equipment, for example surgical instruments, was based on NHS Grampian prices (2008).  The use of pathology services (defined as the microscopic evaluation of the tissue removed during the initial surgery) were also included, where appropriate, with costs based on nationally available estimates [7].  The cost of theatre and recovery rooms were based upon the time spent in theatre and in the recovery room, collected for each trial participant.  These data were combined with a cost per minute of theatre or recovery room time, derived from routine sources [7].  

For each participant the grade of surgeon, assisting surgeon, and anaesthetist present during the procedure were recorded at all participating centres.  Information from one centre, Aberdeen, was used to estimate the type and grade of other members of staff present (e.g. nursing staff in theatre and in the recovery room).  The time spent by each participant in both theatre and recovery room were combined with data on the cost per minute for each type and grade of staff.  Theatre time was defined as the time the patient entered the anaesthetic room to the time the patient left the theatre to go to a recovery room.  Costs per minute were derived from nationally available wage rates plus superannuation and employer national insurance contributions [8].

Length of hospital stay was recorded for each participant.  These data were combined with a cost per in-patient night derived from routine sources [7].  Transport costs subsidised by the NHS were also recorded and costed.  Estimates of the cost per patient of all of the above categories were summed to provide total cost per index intervention for each trial participant.

2.	Resources and costs related to the use of other secondary care services
Other secondary care costs were divided into four main categories: (1) the cost of additional eye surgery over the follow-up period, (2) all subsequent inpatient and/or outpatient visits documented at three and six months post intervention, (3) prescription costs over the follow-up period, and (4) NHS travel costs.

All additional eye surgery documented in case report forms at the three and six month follow-up visits post intervention, were costed using Health Care Resource Group (HRG) information unless they were ILM peel or macular hole surgery, which were costed using the information collected during the trial.  The time taken to conduct an additional ILM peel and macular hole surgery was assumed to take half as much time as the original surgery (given that phacoemulsification and removal of the vitreous would not be performed).  

Additional inpatient stays and outpatient visits that occurred over the six month follow-up period were also costed.  Additional stay was costed using the methods described above and the cost of outpatient visits was based on the number of outpatient visit multiplied by the average cost of a visit [7].  

Medications costs were based on information on the number and type of prescriptions each participant had in the previous six months.  Costs were based on data taken from the BNF (57).

3.	Resources and costs related to the use of primary care
Information on primary care resource use was collected using a participant completed questionnaire administered at the six month follow-up period.  Participants provided information on their use of primary care health services in the previous six months.  This included GP visits, GP nurse visits and optometrist visits.  The number of visits made to each type of care provider was multiplied by an average cost per consultation using routine data sources [8].  

Health related outcomes
QALYs were estimated for each participant from the responses to the EQ-5D questionnaire, administered at baseline and at six months post intervention.  The EQ-5D is widely used instrument for the measurement of the health related quality of life of trial participants [9].  Differences in mean QALYs between randomised groups were estimated, adjusting for baseline EQ-5D scores and for minimisation variables including: lens status, stage of the macular hole, and duration of the macular hole.

Data analysis
The economic analysis was based on the intention to treat principle.   The results are presented as point estimates of mean incremental costs, QALYs, and incremental cost per QALY.  Measures of variance for these outcomes involved bootstrapping estimates of costs, QALYs, and incremental cost per QALY.  Incremental cost-effectiveness data is presented in terms of cost-effectiveness acceptability curves (CEACs).  Other forms of uncertainty were addressed using sensitivity analyses.  

All data was analysed using SPSS v 17 and STATA v 10.  In the base case analysis, missing resource use data were assumed to be missing at random.  The exception to this was where data were missing on the length of stay for the index admission.  In these cases, the index admission was assumed to be a day case.  

Missing EQ-5D responses were not assumed to be missing at random.  Where EQ-5D scores were missing they were imputed taking the mean EQ-5D score of the group (ILM peel and no peel) for that time period.  In sensitivity analyses an extreme value imputation was used to illustrate the effect of uncertainty on conclusions.  

RESULTS




Resource use and costs
Table 1 shows the unit costs for the intervention, secondary care services and primary care services.  There are two differences in the unit costs of the intervention between Peel and No Peel.  These were related to the cost of the dye (trypan blue) and the cost of re-usable forceps used for ILM peeling.  In addition, a pathology cost was included in the Peel group.

Table 2 details the resource use for the Peel and No Peel arm of the trial.  Theatre time and the number of days a patient was admitted following the index procedure were slightly higher in the Peel arm of the trial.  In terms of follow-up resource use in secondary care, patients in the No Peel arm were found to have a higher number of further eye surgeries by 6 months (31 in the No peel arm vs. 12 in the Peel arm, p<0.001).  The No Peel arm also had, on average, a higher number of outpatient visits and inpatient admissions.  GP visits were, on average, also higher in the No peel group.  

The pattern of resource use outlined in Table 2 is reflected in the data presented in Table 3, which outlines the average cost per patient by each area of resource use.  Total intervention and admission costs, the cost of the index procedure plus the index inpatient admission cost, was higher in the Peel arm of the trial, reflecting the greater costs of surgery and a higher mean inpatient index admission.  Conversely, follow-up secondary care costs were higher in the No peel arm, where the average cost per patient of additional surgeries was higher.  The mean cost per patient of inpatient stays over the six month period was higher in the No Peel arm.   

Combining all three areas of resource use, the Peel arm of the trial was found to be less costly than the No Peel arm.  This result was driven mainly by the additional cost of further surgeries in the No Peel arm.  The average cost per patient of macular hole surgery with ILM peel was found to be £2550.  The average cost per patient of macular hole surgery without ILM peel was found to be £2974.  The mean additional cost of surgery without ILM peel was £424 (95% CI -182 to 1045).


Quality adjusted life years
At baseline there were six missing EQ-5D values; at six months there were 26 missing EQ-5D values.  Table 4 shows EQ-5D scores at baseline and six months post intervention and QALY values.  QALYs were very slightly higher on average, after adjusting for differences in baseline EQ-5D and other minimisation variables, in the Peel arm (mean difference 0.002 additional QALYS in the Peel arm) but this difference was not statistically significant (p= 0.785). 

Estimation of cost-effectiveness
On average, Peel was found to be less costly and more effective and dominated the No Peel alternative.  Due to statistical imprecision surrounding these data bootstrapping was used to produce confidence intervals around differences in costs and QALYs.  The incremental cost-effectiveness plane (Figure 1) plots the differences in mean costs and effects into four quadrants (1) Peel is more costly and more effective (NE quadrant) (2) Peel is less costly and more effective (SE quadrant) (3) Peel is more costly and less effective (NW quadrant) and (4) Peel is less costly and less effective (SW quadrant).  

The statistical imprecision surrounding estimates of cost-effectiveness is presented in terms of a CEAC, which represents, at different willingness to pay thresholds, the probability that Peel can be considered to be cost effective (Figure 1b).  Figure 1b demonstrates that if society is not willing to pay anything for an additional QALY there is a 90% chance that ILM Peel is cost-effective.  This result held for all values of willingness to pay up to £40,000, a threshold beyond that adopted by the National Institute for Health and Clinical Effectiveness.  

Sensitivity analysis
A number of sensitivity analyses were conducted to test the robustness of our results.  This included using disposable forceps for ILM rather than reusable forceps and reducing the cost of additional operations by between 50-80%.  Sensitivity analysis was also conducted on the imputation methods for missing EQ-5D information.  This involved imputing the extreme (high and low) values in each peel and no peel groups.  Results of sensitivity analysis showed that the results were not sensitive to changes in the cost of additional operations or the use of disposable forceps.  Results were found to be sensitive to the extreme value imputation for missing EQ-5D values.  When we imputed the extreme low values, the probability that peel was considered cost-effective at a willingness to pay threshold of £20,000 reduced to 35%.  It should be noted that given our knowledge of quality of life after surgery it is not very plausible that participants for whom EQ-5D data were missing had such poor quality of life.

Discussion
The results indicate that ILM peeling offers small, non-statistically significant health gain in terms of QALYs and is likely to be cost-saving (90% of the bootstrapped iterations were found to be cost saving).  The cost savings are primarily due to the higher number of re-operations required in the No peel arm of the trial.  The economic evaluation suggests that ILM peel is likely to be a cost-effective option for macular hole surgery, and is likely to be less costly and provide similar benefits measured in terms of QALYs than no ILM peeling. 
 
There are a number of limitations to consider when interpreting these results.  For example, the cost data were primarily derived from a single participating centre.  Such data may not represent the costs faced by other centers, although we have no evidence to suggest that these costs are not informative.  In addition, costs (and quality of life) were only estimated for the short follow-up of the study.  One issue with our study is that in terms of vision, we have provided evidence that ILM peeling will result, on average, in an improvement of 13 ETDRS letters (as measured by using Early Treatment Diabetic Retinopathy Study visual acuity charts [5,6] at 6 months following surgery.  However there was no evidence of a difference between groups in quality of life at six months.  This might be because the EQ-5D is insensitive to changes in vision in an affected eye; it may also be because participants who were judged to have failed on the index operation quite rapidly received further treatment which would, if successful, tend to increase their quality of life.






A FTMH is a common cause of impaired vision.  Internal limiting membrane (ILM) peeling appears to increase the success of macular hole surgery.   To our knowledge this is the first full economic evaluation of the cost-effectiveness of ILM peeling for the treatment of full-thickness macular hole (FTMH).   It is concluded that ILM peeling is a cost-effective treatment of FTMH compared with no-peeling techniques. 
TABLE 1:	UNIT COSTS (£)
Resource use	Peel	No Peel
Cost of intervention
Cost per general anaesthetic (drugs + equipment)	100.72	100.72
Cost per local anaesthetic (drugs + equipment)	4.26	4.26
Cost of other equipment (macular hole surgery)	270.91	237.80
Pathology costs	31.80	0.00
Cost per minute of theatre time (capital)	4.12	4.12
Cost per minute of recovery room time (capital)1	0.32	0.32
Cost per minute Consultant 	1.30	1.30
Cost per minute Consultant Anaesthetist	1.30	1.30
Cost per minute Registrar Group (SHO & Training Fellow)	0.67	0.67
Cost per minute Staff Grade	0.74	0.74
Cost per minute Associate Specialist	0.94	0.94
Cost per minute of theatre staff2	1.60	1.60
Cost per minute of recovery room staff3	0.22	0.22
Cost per inpatient stay (per night)	549.00	549.00
Cost per day case	349.00	349.00
NHS travel – Hospital car per journey	21.57	21.57
NHS travel – Ambulance car service	8.47	8.47
		
Follow-up costs – Secondary care
Inpatient night 	549.00	549.00
Outpatient visit	117.00	117.00
NHS travel – Hospital car per journey	21.57	21.57
NHS travel – Ambulance car service	8.47	8.47
		




1Based on a recovery room with 13 beds which is running at capacity
2 Based on two Band 2 nurses and four Band 5 nurses present in Theatre




TABLE 2:	NHS RESOURCE USE 
Resource use	Peel (71)(SD/Median)	No Peel (67)(SD/Median)	Mean Diff
Intervention (missing data)
Numbers receiving General anaesthetic 	28	35	
Numbers receiving Local Anaesthetic (6)	39 	30	
Number of day cases	4	5	
Number of inpatient cases	48	47	
Theatre time Mean (minutes)*  	88.56  (41.3/100.0)	86.0 (33.42/90.0)	2.56
Recovery room time Mean (minutes)	14.35 (21.1/0)	16.6 (22.7/0)	-2.25
Number of days admitted after procedure Mean  (SD/median) (34)	1.55 (2.27/1)	1.34 (1.42/1)	0.21
NHS travel –Hospital car	2	2	
NHS travel – Ambulance car	1	0	
			
Follow-up resource use – Secondary care
Any further eye surgery by 6 months	12	31	
Outpatient visits Mean (14)	0.23 (0.88/0)	0.54 (1.15/0)	-0.31
Inpatient nights Mean (13)	0.45 (1.5/0)	0.9 (2.89/0)	-0.45
NHS travel –Hospital car	2	1	
NHS travel – Ambulance car	2	0	
			
Follow up resource use – Primary care
GP visits  Mean (20)	0.14(0.49/0)	0.36 (0.9/0)	-0.22
Nurse visits Mean (26)	0.08(0.44/0)	0.04 (0.21/0)	0.04













TABLE 3:	AVERAGE COST PER PATIENT BY EACH AREA OF RESOURCE USE (£)
Resource use	Peel (71)(SD/Median)	No Peel (67)(SD/Median)
Intervention
Mean Index intervention cost  (Anaesthetic drugs + equipment + surgical equipment + Staff and capital costs) (8)	1141.43 (337.9/1205.7)	1073.14 (258.3/1080.3)
Mean Index admission cost 	963.62 (1174.8/549.0)	841.64 (691.2/549.0)
Total intervention and admission costs (8)	2141.74 (1264.5/1858.5)	1930.99 (802.1/1629.8)
		
Follow up – Secondary care
Mean cost of additional surgery at 6 months 	106.31 (292.32/0.000)	401.77 (463.91/0.000)
Mean cost of Inpatient stay 	247.44 (834.1/0)	491.64 (1585.2/0)
Mean cost of outpatient visit 	26.37 (103.1/0)	62.87 (134.1/0)
Mean NHS travel costs (index admission + outpatient visits) 	2.65 (12.4/0)	1.29 (7.4/0)
Prescription costs at 6 months (1)	2.09 (3.74/0)	2.99 (4.38/1.77)
Total mean secondary care costs (1)	363.97 (1086.4/2.32)	969.02 (1799.1/47.5)
Follow-up – Primary care
Mean cost of GP visits 	5.07 (17.5/0)	12.90 (32.4/0)
Mean cost of Nurse visits 	0.76 (3.95/0)	0.40 (1.9/0)
Mean cost Optometrist visit  	25.35 (33.5/0)	24.72 (32.7/0)
Total mean primary care costs	31.2 (41.5/0)	38.01 (54.99/36.0)




	PEEL 	95% CI	No Peel  	95% CI	Mean difference	P-value
						
EQ5D*						
Baseline 	0.800	0.7535 – 0.8464	0.8776	0.8455 – 0.9097	-0.0776	
6 months 	0.8533	0.8117 – 0.8950	0.8742	0.8404 – 0.9080	-0.0209	0.441
						
QALYs 	0.4133	0.3950 – 0.4316	0.4380 	0.4242 – 0.4517	-0.0247	0.035
						
QALYs (adjusted for all minimisation variables**)					0.002	0.785
















* Missing EQ5D values have been imputed by taking the mean EQ5D score in each treatment group for the missing time period
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